Edwards Lifesciences Corporation (EW) - News Archive

In a significant development for the cardiovascular medical device sector, Edwards Lifesciences Corporation (NYSE: EW) has announced that the United States Federal Trade Commission (FTC) has moved to block its proposed...

In an era marked by remarkable advancements in cardiac care, two recent announcements from Edwards Lifesciences highlight significant strides in valve technology aimed at enhancing the quality of life for patients with...

Edwards Lifesciences Faces Legal and Financial Challenges Amidst Declining Revenue Productivity In recent developments, Edwards Lifesciences Corporation (NYSE: EW) is prompting attention from investors and analysts alik...

Levi & Korsinsky, LLP, a prominent law firm specializing in securities litigation, has drawn attention to an impending class action lawsuit aimed at Edwards Lifesciences Corporation (NYSE: EW). Investors are being remin...

In the intricate world of cardiac intervention, where every heartbeat matters, Edwards Lifesciences stands at the forefront of medical innovation with its SAPIEN 3 Ultra RESILIA valve. Recently showcased at the prestigi...

In a striking turn of events, Edwards Lifesciences Corporation (NYSE: EW) is facing a class action lawsuit as investors react to a staggering market capitalization loss amounting to $16 billion. The prominent medical te...

Breaking Barriers: All-Female TAVI Trial Demonstrates Exceptional Outcomes Using Edwards Valves In a landmark achievement for both medical science and gender-specific healthcare, the first all-female TAVI (transcatheter...

In a historic first for cardiovascular medicine, the all-female transcatheter aortic valve implantation (TAVI) trial has demonstrated excellent outcomes for patients using Edwards Lifesciences Corporation s valves. This...

Sophisticated Five-Year Study Shows Positive Outcomes for Female and Small Annulus Patients in Edwards TAVR Trials, Despite Economic ConcernsEdwards Lifesciences recently released findings from a comprehensive analysis...

Five-Year Data Show Positive Outcomes for Female and Small Annulus Patients with Edwards TAVREdwards Lifesciences, a leading medical device company, has released encouraging results from an analysis of data obtained fro...

Edwards Lifesciences Sells Critical Care Unit to BD in $4.2 Billion Deal: Focus Shifts to Strategic GrowthEdwards Lifesciences, a leading medical technology company, has announced that it will sell its Critical Care pro...

Edwards Lifesciences, a leading medical device company, has announced the promising results from two large, real-world studies conducted using TVT Registry data. The studies highlight the continued success of patients t...

In a breakthrough announcement, Edwards Lifesciences Corporation has received U.S. Food and Drug Administration (FDA) approval for its EVOQUE tricuspid valve replacement system. This cutting-edge transcatheter therapy m...

Edwards Lifesciences Outlines Growth Strategy and Technology Pipeline at Investor ConferenceEdwards Lifesciences Corporation, a leading medical technology company, recently held its annual investor conference where it u...